中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 3
Mar.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(3): 582-586

Clinical features of patients with severe acute respiratory syndrome coronavirus 2 Delta variant infection and abnormal liver function in Guangdong Province, China

DOI: 10.3969/j.issn.1001-5256.2022.03.017

  • No. 21 Isolation Ward, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou 510060, China

Research funding:

Medical Scientific Research Foundation of Guangdong Province (B2021302)

More Information
  • Corresponding author: DENG Haohui, gz8hdhh@126.com (ORCID: 0000-0001-5948-9101)
  • Received Date: 2021-08-15
  • Accepted Date: 2021-09-22
  • Published Date: 2022-03-20
    Abstract
  •   Objective  To investigate the clinical features of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant infection and abnormal liver function in Guangdong Province, China.  Methods  The patients with SARS-CoV-2 Delta variant infection who belonged to the same chain of transmission in Guangdong Province (Guangzhou and Foshan) and were admitted to Guangzhou Eighth People's Hospital, Guangzhou Medical University from May 21 to June 18, 2021 were enrolled in this study, and the judgment criteria for liver function were alanine aminotransferase (male/female) > 50/40 U/L, aspartate aminotransferase > 40 U/L, total bilirubin > 26 μmol/L, gamma-glutamyl transpeptidase > 60 U/L, and alkaline phosphatase (ALK) > 125 U/L. Abnormality in any one item of the above criteria was defined as abnormal liver function, and such patients were included in analysis (the patients, aged < 18 years, who had a mild or moderate increase in ALP alone were not included in analysis). Clinical data were compared between the patients with normal liver function and those with abnormal liver function, and the etiology and prognosis of abnormal liver function were analyzed. The Mann-Whitney U test was used for comparison of continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups.  Results  Among the 166 patients with SARS-CoV-2 Delta variant infection, 32 (19.3%) had abnormal liver function with mild-to-moderate increases in liver function parameters, and compared with the normal liver function group, the abnormal liver function group had a significantly higher proportion of critical patients (χ2=38.689, P < 0.001) and significantly higher age and inflammatory cytokines [C-reactive protein type, serum amyloid A, and interleukin-6 (IL-6)](all P < 0.05). Among the 32 patients with abnormal liver function, 13 patients had abnormal liver function on admission (defined as primary group), while 19 patients had normal liver function on admission but were found to have abnormal liver function by reexamination after treatment (defined as secondary group). For the primary group, the evidence of abnormal liver function was not found for 3 patients (3/13, 23.1%), and the possibility of toxic liver injury directly associated with SARS-CoV-2 infection was considered. Among the 19 patients in the secondary group, 9 (47.4%) had mild/common type and 10 (52.6%) had critical type, and all critical patients had the evidence of liver injury indirectly caused by the significant increases in C-reactive protein type, serum amyloid A, and IL-6 and hypoxemia; the evidence of abnormal liver function was not found for only 1 patient (1/19, 5.3%), and the possibility of toxic liver injury directly associated with SARS-CoV-2 infection was considered. All 32 patients with abnormal liver function had [JP2]significant reductions in liver function parameters after treatment including liver protection.  Conclusion  As for the patients with SARS-CoV-2 Delta variant infection who belong to the same chain of transmission in Guangdong Province, the critical patients show a significantly higher proportion of patients with abnormal liver function than the patients with other clinical types, and other factors except SARS-CoV-2 infection and indirect injury caused by SARS-CoV-2 infection are the main cause of liver injury.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    National Health Commission of the People's Republic of China. Diagnosis and treatment plan for COVID-19 (trial version 8)[J]. Chin J Clin Infect Dis, 2020, 13(5): 321-328. DOI: 10.3760/cma.j.issn.1674-2397.2020.05.001.

    中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第八版)[J]. 中华临床感染病杂志, 2020, 13(5): 321-328. DOI: 10.3760/cma.j.issn.1674-2397.2020.05.001.
    [2]
    DANAN G, TESCHKE R. RUCAM in drug and herb induced liver injury: The update[J]. Int J Mol Sci, 2015, 17(1): 14. DOI: 10.3390/ijms17010014.
    [3]
    VAN OOSTERHOUT C, STEPHENSON JF, WEIMER B, et al. COVID-19 adaptive evolution during the pandemic—Implications of new SARS-CoV-2 variants on public health policies[J]. Virulence, 2021, 12(1): 2013-2016. DOI: 10.1080/21505594.2021.1960109.
    [4]
    GIOVANETTI M, BENEDETTI F, CAMPISI G, et al. Evolution patterns of SARS-CoV-2: Snapshot on its genome variants[J]. Biochem Biophys Res Commun, 2021, 538: 88-91. DOI: 10.1016/j.bbrc.2020.10.102.
    [5]
    MU XC, LI L, WANG LH. Classifications and research progress on prevalent SARS-CoV-2 variants[J]. Int J Virol, 2021, 28(4): 336-340. DOI: 10.3760/cma.j.issn.1673-4092.2021.04.018.

    穆雪纯, 李丽, 王凌航. 新型冠状病毒流行变异株的分型及研究进展[J]. 国际病毒学杂志, 2021, 28(4): 336-340. DOI: 10.3760/cma.j.issn.1673-4092.2021.04.018.
    [6]
    CHOUDHARY J, DHEEMAN S, SHARMA V, et al. Insights of severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic: A current review[J]. Biol Proced Online, 2021, 23(1): 5. DOI: 10.1186/s12575-020-00141-5.
    [7]
    CHEN N, ZHOU M, DONG X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study[J]. Lancet, 2020, 395(10223): 507-513. DOI: 10.1016/S0140-6736(20)30211-7.
    [8]
    CHEN KY, LIAN JS, XU S, et al. Impairment of liver function in patients with COVID-19: An analysis of 85 cases[J]. Chin J Clin Infect Dis, 2020, 13(4): 291-294. DOI: 10.3760/cma.j.issn.1674-2397.2020.04.008.

    陈柯颖, 连江山, 许珊, 等. 新型冠状病毒肺炎85例患者肝功能损伤研究[J]. 中华临床感染病杂志, 2020, 13(4): 291-294. DOI: 10.3760/cma.j.issn.1674-2397.2020.04.008.
    [9]
    CAI Y, YE LP, SONG YQ, et al. Liver injury in COVID-19: Detection, pathogenesis, and treatment[J]. World J Gastroenterol, 2021, 27(22): 3022-3036. DOI: 10.3748/wjg.v27.i22.3022.
    [10]
    WU H, LIU S, LUO H, et al. Progress in the clinical features and pathogenesis of abnormal liver enzymes in coronavirus disease 2019[J]. J Clin Transl Hepatol, 2021, 9(2): 239-246. DOI: 10.14218/JCTH.2020.00126.
    [11]
    STASI C, FALLANI S, VOLLER F, et al. Treatment for COVID-19: An overview[J]. Eur J Pharmacol, 2020, 889: 173644. DOI: 10.1016/j.ejphar.2020.173644.
    [12]
    YANG P, XU KJ, KONG LM, et al. Liver injury caused by antiviral agents for COVID-19[J]. Chin J Clin Infect Dis, 2020, 13(2): 102-108. DOI: 10.3760/cma.j.issn.1674-2397.2020.02.004.

    阳平, 徐凯进, 孔丽敏, 等. 新型冠状病毒肺炎治疗中抗病毒药物引起的肝损伤[J]. 中华临床感染病杂志, 2020, 13(2): 102-108. DOI: 10.3760/cma.j.issn.1674-2397.2020.02.004.
    [13]
    LI GM, PAN X. Features of liver injury in patients with coronavirus disease 2019 in Bozhou, China[J]. J Clin Hepatol, 2020, 36(4): 772-774. DOI: 10.3969/j.issn.1001-5256.2020.04.012.

    李光明, 潘昕. 28例亳州市新型冠状病毒肺炎患者肝损伤的特征分析[J]. 临床肝胆病杂志, 2020, 36(4): 772-774. DOI: 10.3969/j.issn.1001-5256.2020.04.012.
    [14]
    SUN DW, ZHANG D, TIAN RH, et al. Influencing factors and clinical significance of liver function damage in patients diagnosed with COVID-19[J]. Chin J Dig Surg, 2020, 19 (4): 360-365. DOI: 10.3760/cma.j.cn115610-20200229-00133.

    孙大伟, 张东, 田润辉, 等. 新型冠状病毒肺炎肝功能损害的影响因素分析及其临床意义[J]. 中华消化外科杂志, 2020, 19 (4): 360-365. DOI: 10.3760/cma.j.cn115610-20200229-00133.
    [15]
    LI R, QIAO S, ZHANG G. Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV[J]. J Infect, 2020, 80(4): 469-496. DOI: 10.1016/j.jinf.2020.02.013.
    [16]
    CHAI XQ, HU LF, ZHANG Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection[J]. bioRxiv, 2020. DOI: 10.1101/2020.02.03.931766.[Preprint]
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (650) PDF downloads(47) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return